<div id="readability-page-1"><p>MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) is anticipated to issue its  Q1 2026 results before the market opens on Friday, May 8th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors can check  the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:00 PM ET.</p><div><p><span></span><span>Get <strong>MAIA Biotechnology</strong> alerts:</span></p></div><p>MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. </p><h2>MAIA Biotechnology Stock Performance</h2><p>NYSEAMERICAN MAIA opened at $1.33 on Friday. MAIA Biotechnology has a 52 week low of $0.87 and a 52 week high of $3.19. The stock has a market capitalization of $80.69 million, a P/E ratio of -1.93 and a beta of 0.30. The stock has a fifty day moving average of $1.51 and a 200-day moving average of $1.52. </p><h2>Institutional Trading of MAIA Biotechnology</h2><p>Large investors have recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in shares of  MAIA Biotechnology in the second quarter worth about $29,000.  Jane Street Group LLC acquired a new position in  MAIA Biotechnology in the 2nd quarter worth $52,000.  Finally, Geode Capital Management LLC raised its stake in shares of  MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after purchasing an additional 7,746 shares during the period. Institutional investors own  5.65% of the company's stock. </p><h2>About MAIA Biotechnology</h2> (Get Free Report)<p>MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.  </p><p>The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than MAIA Biotechnology</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0VBTUVSSUNBTiZTeW1ib2w9TUFJQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0VBTUVSSUNBTiZTeW1ib2w9TUFJQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in MAIA Biotechnology Right Now?</h2><p>Before you consider MAIA Biotechnology, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.</p><p>While MAIA Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MAIA

LABU

ARKG

SBIO

<p>MAIA Biotechnology (NYSEAMERICAN:MAIA) is set to release its Q1 2026 earnings on May 8, with analysts predicting a loss of $0.18 per share. The company previously reported a loss of $0.08 per share, exceeding expectations. MAIA's stock opened at $1.33, with a market cap of $80.69 million. Institutional investors hold 5.65% of the stock, with recent acquisitions by Marshall Wace LLP and Jane Street Group LLC. MAIA focuses on developing monoclonal antibody conjugates for cancer treatment and imaging.</p>

MAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on Friday